The Primary biliary cholangitis treatment market growth consists of drugs administered to manage primary biliary cholangitis (PBC), an autoimmune condition that damages and destroys bile ducts in the liver over time. Drugs offered under this market include ursodeoxycholic acid, obeticholic acid, and other novel pipeline candidates being developed to provide additional treatment options. Primary biliary cholangitis predominantly affects women, and if left untreated, the bile duct damage can progress to fibrosis and cirrhosis. The increasing prevalence of PBC globally is prompting drug manufacturers to develop advanced treatment alternatives.
The global primary biliary cholangitis treatment market is anticipated to witness substantial growth during the forecast period (2023-2030). It is projected to expand from US$ 650 million in 2023 to reach US$ 1,174.1 million by 2030, exhibiting a compound annual growth rate (CAGR) of 8.8%.
Key Takeaways
Key players operating in the Primary Biliary Cholangitis Treatment Market Analysis are Intercept Pharmaceuticals, Inc., Highlight Therapeutics, S.L., and GSK. Intercept Pharmaceuticals' obeticholic acid (Ocaliva) has been a blockbuster drug for PBC. In terms of the approval and launch of new drugs combined with geographical expansion plans by key players are anticipated to boost market growth. For instance, Highlight Therapeutics is developing new FXR agonists that are potentially safer than existing treatments. Global expansion strategies by major players also pose new opportunities. Intercept Pharmaceuticals announced strategic plans to widen Ocaliva's reach beyond key global markets. GSK also focuses on geographic expansion of PBC drugs into emerging markets.
Market Drivers
Increasing prevalence of PBC worldwide due to improved diagnostic capabilities and growing awareness among physicians and patients is a major growth driver. According to recent epidemiological studies, the disease impacts approximately 1 in 1,000 individuals globally.
Market Restraints
High cost of PBC drug treatment poses a significant restrain. For instance, the annual cost of Ocaliva ranges from $70,000–$100,000 in the US. Restrictive reimbursement policies in certain regions also hamper market growth to some extent.
Segment Analysis
Primary Biliary Cholangitis Treatment market is segmented on the basis of treatment type, distribution channel and regions. By treatment type, Ursodeoxycholic Acid (UDCA) dominates the market. It accounted for over 50%
market share in 2023. UDCA helps improve liver enzyme levels and slow disease progression. However, some patients do not respond adequately to UDCA treatment and require second line treatment options. Fibrates are commonly prescribed second line treatment and expected to be the fastest growing segment during the forecast period. By distribution channel, hospital pharmacies hold the largest share owing to higher patient volume and specialized care for autoimmune liver diseases in hospitals.
Global Analysis
North America remains the dominant region in the Primary Biliary Cholangitis Treatment market accounting for over 40% share in 2023. Higher disease awareness, availability of advanced treatment options and favorable reimbursement scenario drive the North America market. Europe is the second largest market supported by high healthcare spending and universal healthcare coverage. Asia Pacific is expected to witness the highest growth during the forecast period due to increasing patient diagnosis, improving affordabilityand healthcare infrastructure growth. Regional expansion plans of key players in emerging countries would further accelerate growth rates in Asia Pacific region.
Get More Insights On- Primary Biliary Cholangitis Treatment Market
Get This Report In Japanese-
Get This Report In Korean-
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91 )
Jul 19, 2019 (AB Digital via COMTEX) -- Huntington’s Disease Treatment Market size to grow at a CAGR of 40% over the forecast period (2018-2023).
The individuals suffering from this disorder may have trouble in walking, speaking, and swallowing.
People with this disorder also experience decline in thinking and reasoning abilities.
Individuals suffering with this huntington disease usually live about 15 to 20 years after signs and symptoms begin.
Huntington’s disease treatment market is expected to grow in the near future due to rise in incidence of genetic diseases, increasing research and development activities to develop drugs that can be used for treatment of this disorder and developing healthcare sector.
Key players in market are making their position in many developing countries due to the FDI policies regulated within the pharmaceuticals industry in such countries with increasing consumer demands towards maintaining aesthetic appearance is also driving the market for global huntington’s disease treatment market.
